

HPGD Antibody (C-term) Blocking Peptide
Synthetic peptide
Catalog # BP6794b**Specification**

HPGD Antibody (C-term) Blocking Peptide - Product InformationPrimary Accession [P15428](#)**HPGD Antibody (C-term) Blocking Peptide - Additional Information**

Gene ID 3248

Other Names

15-hydroxyprostaglandin dehydrogenase [NAD(+)], 15-PGDH, Prostaglandin dehydrogenase 1, HPGD, PGDH1

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP6794b](/products/AP6794b) was selected from the C-term region of human HPGD. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

HPGD Antibody (C-term) Blocking Peptide - Protein InformationName HPGD ([HGNC:5154](#))

Synonyms PGDH1, SDR36C1

Function

Catalyzes the NAD-dependent dehydrogenation (oxidation) of a broad array of hydroxylated polyunsaturated fatty acids (mainly eicosanoids and docosanoids, including prostaglandins, lipoxins and resolvins), yielding their corresponding keto (oxo) metabolites (PubMed: [8086429](http://www.uniprot.org/citations/8086429), PubMed: [10837478](http://www.uniprot.org/citations/10837478), PubMed: [16828555](http://www.uniprot.org/citations/16828555), PubMed: [16757471](http://www.uniprot.org/citations/16757471), PubMed: [21916491](http://www.uniprot.org/citations/21916491), PubMed: [25586183](http://www.uniprot.org/citations/25586183)). Decreases

the levels of the pro- proliferative prostaglandins such as prostaglandin E2 (whose activity is increased in cancer because of an increase in the expression of cyclooxygenase 2) and generates oxo-fatty acid products that can profoundly influence cell function by abrogating pro-inflammatory cytokine expression (PubMed:25586183, PubMed:15574495). Converts resolvins E1, D1 and D2 to their oxo products, which represents a mode of resolvins inactivation. Resolvin E1 plays important roles during the resolution phase of acute inflammation, while resolvins D1 and D2 have a unique role in obesity-induced adipose inflammation (PubMed:16757471, PubMed:22844113).

Cellular Location

Cytoplasm.

Tissue Location

Detected in colon epithelium (at protein level).

HPGD Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

HPGD Antibody (C-term) Blocking Peptide - Images**HPGD Antibody (C-term) Blocking Peptide - Background**

HPGD is a member of the short-chain nonmetalloenzyme alcohol dehydrogenase protein family. This protein is responsible for the metabolism of prostaglandins, which function in a variety of physiologic and cellular processes such as inflammation.

HPGD Antibody (C-term) Blocking Peptide - References

Thill,M., et.al., Anticancer Res. 29 (9), 3619-3625 (2009)